Leukaemia (chronic lymphocytic, relapsed) - rituximab: notice of appeal

The Institute has received two appeals against the Final Appraisal Determination and Guidance on this technology. In this case, the Chairman of the Appeal Committee, Dr Margaret Helliwell has decided that the nature of the appeal is such that it can be determined on the basis of written submissions. The Institute will not, therefore, be holding a public appeal hearing and appellants will not be required to attend to answer questions from the Panel. 

The appellant’s letters will be passed to the Chairman of the Appraisal Committee, who will prepare a response.  This response will be passed to the appellants for comment.  The initial appeal letters, the response from the Chairman of the Appraisal Committee, the appellant’s reply to that response, and key documents considered by the Committee during the appraisal will then be considered by the Appeal Panel.

The names of the appellants will be published on the Institute’s web site on the day the Panel convenes.  The Institute will not comment on speculation as to the identity of appellants prior to publication of this information on the Institute’s website.

The Appeal Panel will convene to consider the written appeal papers on Tuesday 25th May 2010.

This page was last updated: 16 August 2010